(PharmaNewsWire.Com, December 02, 2021 ) MarketsandMarkets Research Report’s View on Revenue Impact?
The Global Lymphedema Diagnostics Market is projected to reach USD 35 million by 2024 from USD 24 million in 2019, at a CAGR of 7.4%
Factors Responsible for Growth and In-Depth Analysis?
The growing global prevalence of lymphedema and cancer; technological advancements in diagnostic imaging modalities; and increasing investments, funds, and grants by public-private organizations are the major factors driving the growth of this market. However, the high cost of diagnostic imaging systems, the short half-life of radiopharmaceuticals, the limited supply of helium, and the increasing adoption of refurbished diagnostic imaging systems are expected to restrain the growth of this market.
- To define, describe, and forecast the market on the basis of technology, disease type, end user, and region
- To provide detailed information regarding the major factors influencing the growth of this market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the total market
The major players operating in the lymphedema diagnostics market are GE Healthcare (US), Philips (Netherlands), and Siemens Healthineers (Germany). Other prominent players in this market include Canon, Inc. (Japan), Shimadzu Corporation (Japan), Stryker Corporation (US), Fluoptics (France), United Imaging Healthcare Co., Ltd. (China), Hitachi, Ltd. (Japan), Esaote, SpA (Italy), Neusoft Corporation (China), Mindray Medical International, Ltd. (China), Mitaka USA, Inc. (US), Curadel, LLC (US), and ImpediMed Ltd. (Australia).
GE Healthcare (US) is one of the leading players in the global lymphedema diagnostics market. To sustain its leadership position and ensure its future growth, the company has been focusing on product launches and agreements, partnerships, and collaborations as its key strategies. The company has also been focusing on geographic expansions and the development of low-cost equipment specifically for developing nations. For instance, in May 2017, the company collaborated with the Government of Egypt to supply a wide range of technologies and train doctors, nurses, and technicians about advanced imaging systems in over 200 Egyptian hospitals. With a wide product portfolio and strong geographic presence, the company is expected to witness significant growth in the lymphedema diagnostics market in the coming years.
Geographical Analysis in Detailed?
North America to dominate the lymphedema diagnostics market during the forecast period
The lymphedema diagnostics therapy market is segmented into four regional segments, namely, North America, Europe, the Asia Pacific, and the Rest of the World. The large share of North America can be attributed to factors such as the easy availability and rapid adoption of technologically advanced imaging systems; high incidence/prevalence of lymphedema; and the strong, well-established healthcare systems. The market in the Asia Pacific is expected to grow at the highest rate, followed by Europe.
The lymphoscintigraphy segment accounted for the largest share of the lymphedema diagnostics market in 2018.
Based on technology, segmented into lymphoscintigraphy, magnetic resonance imaging (MRI), ultrasound imaging, computed tomography (CT), X-ray lymphography, bioimpedance analysis, and near-infrared fluorescence imaging. In 2018, the lymphoscintigraphy segment accounted for the largest share of the lymphedema diagnostic market. The noninvasive nature and easy reproducibility of this technology, and the fact that lymphoscintigraphy does not adversely affect the lymphatic vascular endothelium are some of the key advantages supporting the adoption of this technology.
The cancer segment accounted for the largest share of the lymphedema diagnostics market in 2018.
On the basis of disease type, segmented into cancer, inflammatory diseases, cardiovascular disease, and other diseases (congenital abnormalities, trauma-related conditions, infections, and filariasis). The cancer segment accounted for the largest share of the lymphedema diagnostics therapy market in 2018. The large share of this segment can be attributed to the rising prevalence of cancer-associated lymphedema and increasing awareness about early disease diagnosis.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
